San Diego, California - Newsfile Corp. - December 2, 2024 - Ainos, Inc. (NASDAQ: AIMD) (NASDAQ: AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today proudly announced the signing of a strategically significant Memorandum of Understanding (MOU) with Taiwan Tanabe Seiyaku Co., Ltd., a subsidiary of Mitsubishi Tanabe Pharma Corporation in Japan, brings extensive pharmaceutical development and manufacturing expertise to the partnership. The collaboration aims to advance the manufacturing and Taiwan market promotion of Ainos' groundbreaking Sjögren's syndrome drug, VELDONA^®. Both parties may work under the terms of the MOU to further define the partnership. Market Demand for Sjögren's Syndrome Treatment Sjögren's syndrome is an autoimmune disease affecting millions of patients worldwide, with a significant unmet need for effective treatments. As the global population ages and awareness of the disease increases, the demand for therapeutic solutions is growing rapidly. According to market analysis, the global Sjögren's syndrome market is projected to reach billions of dollars in the next five years. Ainos believes VELDONA^® will provide a much-needed, innovative treatment option for millions of patients and fulfill this pressing market demand. VELDONA^®'s Clinical Progress and Success Ainos has dedicated years to the development of Sjögren's syndrome treatments, with VELDONA^®, a low-dose oral interferon-alpha, showing remarkable potential in clinical trials. Previous studies have demonstrated that VELDONA^® can significantly alleviate patient symptoms, improve quality of life, and effectively control disease progression. The drug has shown strong tolerability and safety, establishing a solid foundation for further large-scale global clinical trials. Partnership with Taiwan Tanabe Seiyaku Taiwan Tanabe Seiyaku, as a subsidiary of Mitsubishi Tanabe Pharma, offers extensive experience in pharmaceutical development and market expansion. As part of this partnership, Taiwan Tanabe Seiyaku may collaborate with Ainos on the manufacturing and promotion of VELDONA^® to meet market demand. Both parties will clarify the specific details and responsibilities of the partnership as stipulated in the MOU agreement. Global Market Impact and Future Outlook This collaboration with Taiwan Tanabe Seiyaku will accelerate the global market introduction of VELDONA^®, ensuring that the drug reaches patients in a timely and efficient manner. The formal contract will define the clear rights and responsibilities of both parties, paving the way for long-term success. Ainos anticipates that as more clinical data is collected and the drug becomes available in more markets, the demand for VELDONA^® will solidify its position as a leading treatment for Sjögren's syndrome. Additionally, the success of this drug will open further opportunities in other autoimmune diseases, enhancing the company's market valuation and growth potential. Ainos' Future Vision Ainos is committed to driving medical innovation and addressing the world's unmet medical needs. This partnership with Taiwan Tanabe Seiyaku marks an important milestone in our global strategy, and we will continue to focus on developing breakthrough therapies that improve the quality of life for patients worldwide. About Ainos, Inc. Headquartered in San Diego, California, Ainos is a diversified healthcare company focused on novel AI-powered point-of-care testing (POCT) and low-dose interferon therapeutics (VELDONA^®). The Company's clinical-stage product pipeline includes VELDONA^® human and animal oral therapeutics, human orphan drugs, and telehealth-friendly POCT solutions powered by its AI Nose technology platform. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date. About Taiwan Tanabe Seiyaku Co., Ltd. Taiwan Tanabe Seiyaku Co., Ltd., a subsidiary of Mitsubishi Tanabe Pharma Corporation, was established in 1962. The company is focused on providing high-quality pharmaceutical products and innovative therapeutic solutions in Taiwan and neighboring markets, covering key therapeutic areas such as autoimmune diseases, diabetes, and other major health conditions. Safe Harbor Statement Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-Looking statements can be identified by the use of words such as "anticipate," "believe," "estimate," "approximate," "expect," "intend," "plan," "predict," "project," "target," "future," "likely," "strategy," "foresee," "may," "guidance,"...